COX-2 selective inhibitors: analysis of the renal effects
- 1 May 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 1 (1) , 53-64
Abstract
COX-2 selective inhibitors provide analgesia and blunt inflammation while also sparing the gastrointestinal tract from classic NSAID toxicity. Therapeutic effects are thought to result from inhibit...Keywords
This publication has 44 references indexed in Scilit:
- HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemiaNature Medicine, 2001
- Antiretroviral therapy-associated hyperlipidaemia in HIV diseaseCurrent Opinion in Lipidology, 2001
- Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999Clinical Infectious Diseases, 2000
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infectionInternational Journal of STD & AIDS, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Hyperlipidemia under treatment with proteinase inhibitorsInfection, 1999
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998